QPPV.COM KNOWLEDGE ASSESSMENT

Knowledge Assessment: GVP Module VI, Clinical Trials and ICSR Management

Test your understanding of the concepts covered by GVP Module VI: Clinical Trials and ICSR Management.

Question 1 of 10Pass mark: 80%

Question 1 of 10 Which situation most clearly indicates organisational ambiguity in the clinical-trial safety system?

The sponsor has a controlled reference safety information version history The sponsor and CRO have defined responsibilities and oversight measures Staff cannot determine who receives, assesses, submits and follows up a serious trial safety report The MAH evaluates relevant trial information in aggregate safety activities

Question 2 of 10 Which statement best distinguishes an adverse event from a suspected adverse reaction?

An adverse event is always serious, whereas a suspected adverse reaction is not An adverse event occurs only after treatment, whereas a suspected adverse reaction occurs before treatment An adverse event does not necessarily imply causality, whereas a suspected adverse reaction involves a suspected causal relationship An adverse event is reported to CTIS, whereas a suspected adverse reaction is always reported to EVPM

Question 3 of 10 How should a medication error or misuse in a clinical trial be assessed?

It is automatically a SUSAR because the exposure was outside intended use It should be assessed as a circumstance and in relation to any resulting clinical consequence and applicable expedited criteria It should never be collected because it is not a reaction It must be reported to EVPM regardless of outcome or seriousness

Question 4 of 10 What is the principal distinction between EVCTM and EVPM in the context described by the article?

EVCTM is used for clinical-trial SUSARs, whereas EVPM is used for post-authorisation ICSRs EVCTM is used only by regulators, whereas EVPM is used only by sponsors EVCTM contains aggregate reports, whereas EVPM contains only clinical-trial reports EVCTM is the legacy database, whereas EVPM is the current CTIS application system

Question 5 of 10 Which responsibility remains with the sponsor even when clinical-trial safety activities are delegated to a CRO?

No responsibility, because delegation transfers regulatory accountability Oversight of the CRO and assurance that the trial safety system operates effectively Only responsibility for archiving, while the CRO owns all reporting decisions Responsibility for MAH post-authorisation reporting instead of the MAH

Question 6 of 10 Which feature is most important in reconciliation between separate sponsor and MAH safety systems?

Ensuring every record is duplicated identically in both systems Confirming that relevant information requiring action is transmitted accurately and discrepancies are investigated and resolved Comparing only the number of cases in each database once per year Restricting reconciliation to cases already submitted to EVPM

Question 7 of 10 What should be established before selecting the operational pathway for a safety report arising in a clinical trial?

Whether the product has a marketing authorisation The applicable legal and regulatory framework governing the trial Whether the event was reported by an investigator or a patient Whether the MAH has already entered the event into its database

Question 8 of 10 A medicinal product is authorised, but it is being studied in an interventional clinical trial governed by the Clinical Trials Regulation. Which conclusion is most appropriate?

Every adverse reaction in the trial must automatically be processed as an EVPM case The product's authorisation means that clinical-trial safety reporting no longer applies The trial's legal and methodological classification must be assessed; applicable clinical-trial obligations may continue to apply The MAH automatically becomes the sponsor for all safety reporting

Question 9 of 10 What is the main purpose of SUSAR follow-up?

To replace the initial report with a new case and discard the original To obtain clinically meaningful information, update the assessment and outcome, and maintain traceability to the initial report To transfer ownership of all cases automatically to the MAH To avoid reporting until the patient's final outcome is known

Question 10 of 10 Which control would provide the strongest evidence that a sponsor-MAH safety interface is effective during an inspection?

A detailed written agreement with no supporting operational records A procedure stating that reconciliation is performed, without results Case records, transmission acknowledgements, reconciliation results, follow-up documentation and documented resolution of discrepancies A list of staff names without training or case-handling evidence

Knowledge Assessment: GVP Module VI, Clinical Trials and ICSR Management

Cookie Settings